As regulators and payers increasingly elevate the importance of RWE in submission requirements and with an explosion of datasets opening up in parallel with advancing AI, deep learning, and large language models transforming big data analysis, it has never been more critical to keep up with the matrix of country-specific regulatory nuances and industry case studies in optimizing integrated evidence plans, bullet-proofing data quality, and navigating vendor selection.
The 2nd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE and Evidence Generation to consolidate, innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement.
With a tight focus on leveraging AI for both efficiency gains and big data analysis, the latest on DARWIN and using RWE to support regulatory decision-making, and creating a robust integrated evidence strategy, join 60+ industry pioneers from AstraZeneca, Pfizer, Novartis, Sanofi and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice, ensuring resilience and success in a dynamic landscape as a successful business partner.
URL:
Brochure: https://go.evvnt.com/2850632-3?pid=263
Prices:
Conference + 2 Workshops - Primary - OTD: EUR 3797.00,
Conference + 2 Workshops - Discounted - OTD: EUR 3097.00,
Conference + 2 Workshops - Vendor - OTD: EUR 4597.00,
Conference + 1 Workshop - Primary - OTD: EUR 3298.00,
Conference + 1 Workshop - Discounted - OTD: EUR 2798.00,
Conference + 1 Workshop - Vendor - OTD: EUR 3998.00,
Conference Only - Primary - OTD: EUR 2799.00,
Conference Only - Discounted - OTD: EUR 2399.00,
Conference Only - Vendor - OTD: EUR 3399.00
Speakers: Erwin Bruninx, Senior Medical Advisor RWE, Pfizer, Joan Mendivil, Head Evidence and Outcomes Research, Pharvaris, Lene Hammer-Helmich, Director and Head of Real World Evidence and Epidemiology, Lundbeck, Lill-Brith von Arx, RWE Northern Europe Hub Lead, Eli Lilly, Sebastian Kloss, Global Real World Evidence and Epidemiology Lead, Menarini, Amar Mehta, Senior Real World Evidence Specialist, Lundbeck, Antonella Chiucchiuini, Global Medical Evidence, Fair Market Value Lead, Takeda, Inna Prygova, Head of Global Medical Affairs Strategy and Aesthetics, Galderma, Katoo Muylle, Real World Evidence Manager, AstraZeneca, Luke McGuinness, Senior Manager, Real World Science, Alexion Pharmaceuticals, Marcus Lawrance, Director - Global Oncology and Data Strategy, AstraZeneca, Maurice Timmermans, Head Procurement Real World Evidence Generation and Dissemination, Astellas Pharma, Michael Wallington, Hematology RWE Science and Epidemiology Director, Pfizer, Onyinye Diribe, HEOR Real World Evidence Lead, Sanofi, Ronald Vollebregt, Real World Data Manager, Amgen, Swarna Khare, Director - Immunology and Real-World Evidence, Novartis AG, Tina Roblek, Evidence Generation and Management Lead Managed Care Organization and Electrical Engineering, Takeda
The 2nd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE and Evidence Generation to consolidate, innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement.
With a tight focus on leveraging AI for both efficiency gains and big data analysis, the latest on DARWIN and using RWE to support regulatory decision-making, and creating a robust integrated evidence strategy, join 60+ industry pioneers from AstraZeneca, Pfizer, Novartis, Sanofi and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice, ensuring resilience and success in a dynamic landscape as a successful business partner.
URL:
Brochure: https://go.evvnt.com/2850632-3?pid=263
Prices:
Conference + 2 Workshops - Primary - OTD: EUR 3797.00,
Conference + 2 Workshops - Discounted - OTD: EUR 3097.00,
Conference + 2 Workshops - Vendor - OTD: EUR 4597.00,
Conference + 1 Workshop - Primary - OTD: EUR 3298.00,
Conference + 1 Workshop - Discounted - OTD: EUR 2798.00,
Conference + 1 Workshop - Vendor - OTD: EUR 3998.00,
Conference Only - Primary - OTD: EUR 2799.00,
Conference Only - Discounted - OTD: EUR 2399.00,
Conference Only - Vendor - OTD: EUR 3399.00
Speakers: Erwin Bruninx, Senior Medical Advisor RWE, Pfizer, Joan Mendivil, Head Evidence and Outcomes Research, Pharvaris, Lene Hammer-Helmich, Director and Head of Real World Evidence and Epidemiology, Lundbeck, Lill-Brith von Arx, RWE Northern Europe Hub Lead, Eli Lilly, Sebastian Kloss, Global Real World Evidence and Epidemiology Lead, Menarini, Amar Mehta, Senior Real World Evidence Specialist, Lundbeck, Antonella Chiucchiuini, Global Medical Evidence, Fair Market Value Lead, Takeda, Inna Prygova, Head of Global Medical Affairs Strategy and Aesthetics, Galderma, Katoo Muylle, Real World Evidence Manager, AstraZeneca, Luke McGuinness, Senior Manager, Real World Science, Alexion Pharmaceuticals, Marcus Lawrance, Director - Global Oncology and Data Strategy, AstraZeneca, Maurice Timmermans, Head Procurement Real World Evidence Generation and Dissemination, Astellas Pharma, Michael Wallington, Hematology RWE Science and Epidemiology Director, Pfizer, Onyinye Diribe, HEOR Real World Evidence Lead, Sanofi, Ronald Vollebregt, Real World Data Manager, Amgen, Swarna Khare, Director - Immunology and Real-World Evidence, Novartis AG, Tina Roblek, Evidence Generation and Management Lead Managed Care Organization and Electrical Engineering, Takeda
